Date: 2017-04-29
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Osteoarthritis Research Society International (OARSI) annual meeting
Company: Galapagos (Belgium)
Product: GLPG1972
Action mechanism: enzyme inhibitor/ADAMTS-5 inhibitor. In July 2010, Servier and Galapagos announced their alliance to develop innnovative oral medicines for the treatment of osteoarthritis. Under this agreement, Galapagos is eligible to receive up to €290 million in success-based milestones, plus royalties on sales.
Disease: osteoarthritis
Therapeutic area:
Country:
Trial details:
Latest news: • On April 29, 2017, Galapagos announced presentation of pre-clinical pharmacology data with GLPG1972 at the Osteoarthritis Research Society International (OARSI) annual meeting in Las Vegas. Galapagos disclosed that GLPG1972 is a potent and highly selective inhibitor of ADAMTS-5, a well-established target in the literature for osteoarthritis. ADAMTS-5 is a key enzyme involved in cartilage breakdown (Larkin 2015). At the OARSI 2017 World Congress, Galapagos presents pre-clinical pharmacology data with GLPG1972 showing cartilage protection in both rodent and human explant assays. Disease-modifying activity with GLPG1972 in the gold-standard, destabilization of the medial meniscus (DMM) rodent model will also be presented. "GLPG1972: A POTENT, SELECTIVE, ORALLY AVAILABLE ADAMTS-5 INHIBITOR FOR THE TREATMENT OF OA " Galapagos previously announced that a Phase 1 study in healthy human volunteers demonstrated favorable safety and PK profiles of GLPG1972, and up to 60% reduction in a cartilage breakdown biomarker within two weeks of treatment. This biomarker is serum ARGS-neoepitope, which is formed from cartilage through ADAMTS-5 and thus serves as a biomarker for target engagement. Galapagos plans to initiate a Phase 1b study in osteoarthritis patients in the United States this quarter.
